Identification of Key Blood Molecular Markers for Immunotherapy

Stanford University1 site in 1 country191 target enrollmentJuly 6, 2006

ConditionsSquamous Cell Carcinoma Adenocarcinoma Neoplasms

Overview

Phase: N/A
Intervention: Not specified
Conditions: Squamous Cell Carcinoma
Sponsor: Stanford University
Enrollment: 191
Locations: 1
Primary Endpoint: To identify and evaluate the presence of pre-existing immunity related markers in peripheral human blood, to identify patients who may respond to IL-12 immunotherapy
Status: Terminated
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

To identify unique blood markers in cancer patients so that we can identify patients with evidence of pre-existing immunity who may be a responder to immunotherapy.

Registry

clinicaltrials.gov

Start Date

July 6, 2006

End Date

February 25, 2015

Last Updated

7 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Stanford University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients diagnosed with cancerous tumors based on biopsy or other clinical observations.
•Patients diagnosed with non-cancerous tumors based on biopsy or other clinical observations.
•Normal volunteers who do not have cancer or other medical conditions that may affect survival.

Exclusion Criteria

•Patients will be excluded if, upon clinical observation, they are under a severe septic or inflammatory condition. In these conditions, human body immune response against sepsis or inflammation should be the predominant response, and may shield or block the immune response against tumors.
•Patients will be excluded if, upon clinical observation, they are under extremely illness situation like myocardial infarction. In such a case, the immune findings may be altered.
•Patients will be excluded if, upon looking through their medical records, significant information required for data analysis is missing. This is because that patients' medical records will help us connect our research findings with their clinical observations, and further provide guidelines for subsequent treatment options.

Outcomes

Primary Outcomes

To identify and evaluate the presence of pre-existing immunity related markers in peripheral human blood, to identify patients who may respond to IL-12 immunotherapy

Time Frame: 3 years